Acquiring Company
Vertex Pharmaceuticals
Acquired Company
Crinetics Pharmaceuticals
BostonSan DiegoBiotechnologyHealth CareTherapeuticsBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Vertex Pharmaceuticals has announced its plan to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, totaling approximately $10 billion. This acquisition aims to strengthen Vertex's portfolio with Crinetics' innovative therapies for endocrine diseases, particularly in the fields of acromegaly and congenital adrenal hyperplasia. The deal was unanimously approved by both companies' boards and is anticipated to close in Q3 2026.
Don't miss Vertex Pharmaceuticals's next move
Get an email the moment Vertex Pharmaceuticals makes an acquisition, hires an exec, or expands — usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals was acquired by Vertex Pharmaceuticals, based in Boston. The deal was reported on July 6, 2026. Vertex is a global biotechnology company focused on innovative medicines for serious diseases. Vertex Pharmaceuticals is publicly traded (VRTX) and operates in Biotechnology.
When did Vertex Pharmaceuticals acquire Crinetics Pharmaceuticals?
Vertex Pharmaceuticals's acquisition of Crinetics Pharmaceuticals was reported on July 6, 2026. Vertex Pharmaceuticals has announced its plan to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, totaling approximately $10 billion. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Crinetics Pharmaceuticals do?
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. It is publicly traded (CRNX), operating in Biotechnology, and is based in San Diego.